Tetra Pharm Technologies Advances CB1 Antagonist TPT0701 for Appetite Suppression into Preclinical Testing
Following the successful filing of the Intellectual Property (IP) for its applied platform technology targeting the endocannabinoid system (ECS), Tetra…
